For renal cell carcinoma, trials using the A2AR antagonist CPI‐444 as monotherapy and in combination with the PD‐L1 inhibitor atezolizumab have yielded positive results, with median progression‐free survival (PFS) 4.1 months and 5.8 months, respectively.53 This evidence concerns the gene ADORA2A and renal cell carcinoma.